Stockscreener 앱 받기
20.05
3.19%
-0.66
시간 외 거래:
19.59
-0.46
-2.29%
전일 마감가:
$20.71
열려 있는:
$20.73
하루 거래량:
1.82M
Relative Volume:
1.03
시가총액:
$2.40B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-5.1148
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
+0.65%
1개월 성능:
+14.11%
6개월 성능:
+49.18%
1년 성능:
+105.01%
1일 변동 폭
$19.76
$20.73
1주일 범위
$19.41
$21.56
52주 변동 폭
$8.03
$21.56
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
20.05 | 2.48B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Is Arcutis Biotherapeutics Inc. stock bottoming out2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year HighStill a Buy? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD - Investing.com
Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales - Investing.com
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - BioSpace
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $26 - 富途牛牛
FDA approves ZORYVE cream for atopic dermatitis in young children By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in Stock - MarketBeat
Arcutis Biotherapeutics Hits New 52-Week High of $21.30 - Markets Mojo
FDA Approves Roflumilast Cream 0.05% for Atopic Dermatitis in Children 2 to 5 - Drug Topics
Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children - Investing.com
ARQT: FDA Approves ZORYVE Cream for Young Children's Atopic Dermatitis - GuruFocus
Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5 - Quiver Quantitative
1.8M U.S. children ages 2–5 treated topically — Arcutis' ZORYVE 0.05% FDA‑approved, available Oct 2025 - Stock Titan
Fishman Jay A Ltd. MI Purchases 23,000 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What drives Arcutis Biotherapeutics Inc stock priceMarket Sentiment Extremes & Ride the Wave of Market-Beating Growth - earlytimes.in
Is Arcutis Biotherapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% Following Insider Selling - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% After Insider Selling - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 24,261 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 20,739 Shares - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule - MarketScreener
94,500 RSUs Granted — Arcutis Reports Inducement Grants to 12 New Hires, Vesting Over Four Years - Stock Titan
Will Arcutis Biotherapeutics Inc. stock split attract more investorsOptions Play & Weekly Chart Analysis and Guides - newser.com
Arcutis Biotherapeutics Achieves 101.39% Stock Surge, Establishing It as a Multibagger Performer - Markets Mojo
Arcutis Biotherapeutics Hits New 52-Week High of $20.10, Up 162% - Markets Mojo
AMI Asset Management Corp Sells 94,839 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27% - simplywall.st
Q4 2025 FDA Preview: 10 Decisions to Watch - HCPLive
Arcutis Biotherapeutics Hits New 52-Week High of $19.36 - Markets Mojo
Arcutis Biotherapeutics Hits Day High with Strong 7.29% Intraday Surge - Markets Mojo
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Reviewing BioMarin Pharmaceutical (NASDAQ:BMRN) & Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN
ARQTArcutis Biotherapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week HighWhat's Next? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 18.17 USD By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics stock hits 52-week high at 18.17 USD - Investing.com
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - Yahoo Finance
Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy - sharewise.com
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Share Price Not Quite Adding Up - 富途牛牛
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Exploring a 30.94% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcutis Biotherapeutics Inc 주식 (ARQT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Watanabe Todd | See Remarks |
Oct 01 '25 |
Sale |
19.33 |
24,261 |
469,074 |
867,179 |
| Watanabe Todd | See Remarks |
Oct 02 '25 |
Sale |
20.04 |
20,739 |
415,574 |
846,440 |
| Welgus Howard G. | Director |
Oct 01 '25 |
Option Exercise |
1.68 |
9,538 |
16,030 |
109,744 |
| Welgus Howard G. | Director |
Oct 01 '25 |
Sale |
18.92 |
10,000 |
189,227 |
99,744 |
5.74%
자본화:
|
볼륨(24시간):